<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04057118</url>
  </required_header>
  <id_info>
    <org_study_id>OSCO-P2201</org_study_id>
    <nct_id>NCT04057118</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703 in Patients With Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oscotec Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oscotec Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of SKI-O-703 compared with placebo, in
      patients with active rheumatoid arthritis (RA) who have had an inadequate response to
      conventional synthetic disease-modifying agents. Patients will be randomly assigned to one of
      4 groups and will receive one of three doses of SKI-O-703 or placebo, administered orally
      twice daily for 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">April 14, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 14, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in disease activity score</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Mean change from baseline in disease activity score for 28 joints (DAS28) using hsCRP (high sensitivity C-reactive protein)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Percentage of patients with ACR20 (American College of Rheumatology 20) score</measure>
    <time_frame>Baseline and Weeks 2, 4 8 and 12</time_frame>
    <description>ACR20 score is the percentage of patients showing ≥20% improvement from baseline in tender joint count (68 joint counts), ≥20% improvement in swollen joint count (66 joint counts), and ≥20% improvement in at least 3 of the following: patient's global assessment of arthritis pain; patient's global assessment of disease activity; physician's global assessment of disease activity; health assessment questionnaire-disability index (HAQ-DI); hsCRP (high sensitivity C-reactive protein)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Percentage of patients with ACR50 (American College of Rheumatology 50) score</measure>
    <time_frame>Baseline and Weeks 2, 4 8 and 12</time_frame>
    <description>ACR50 score is the percentage of patients showing ≥50% improvement from baseline in tender joint count (68 joint counts), ≥50% improvement in swollen joint count (66 joint counts), and ≥50% improvement in at least 3 of the following: patient's global assessment of arthritis pain; patient's global assessment of disease activity; physician's global assessment of disease activity; health assessment questionnaire-disability index (HAQ-DI); hsCRP (high sensitivity C-reactive protein)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Percentage of patients with ACR70 (American College of Rheumatology 70) score</measure>
    <time_frame>Baseline and Weeks 2, 4 8 and 12</time_frame>
    <description>ACR70 score is the percentage of patients showing ≥70% improvement from baseline in tender joint count (68 joint counts), ≥70% improvement in swollen joint count (66 joint counts), and ≥70% improvement in at least 3 of the following: patient's global assessment of arthritis pain; patient's global assessment of disease activity; physician's global assessment of disease activity; health assessment questionnaire-disability index (HAQ-DI); hsCRP (high sensitivity C-reactive protein)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire-Disability Index (HAQ-DI) score</measure>
    <time_frame>Baseline and Weeks 2, 4 8 and 12</time_frame>
    <description>Change from baseline measured by disability index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>SKI-O-703 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SKI-O-703 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SKI-O-703 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SKI-O-703</intervention_name>
    <description>Oral administration, twice per day</description>
    <arm_group_label>SKI-O-703 100 mg</arm_group_label>
    <arm_group_label>SKI-O-703 200 mg</arm_group_label>
    <arm_group_label>SKI-O-703 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration, twice per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must provide written, signed, informed consent.

          -  Patients must have a diagnosis of Rheumatoid Arthritis (RA) according to American
             College of Rheumatology (ACR) criteria or the 2010 ACR/European League Against
             Rheumatism classification, for at least 6 months prior to first administration of
             study drug.

          -  Patients must have active RA at screening and baseline (Day 1 of the study).

          -  Patients who have active disease despite csDMARD (conventional synthetic
             disease-modifying antirheumatic drugs) therapy for at least 3 months prior to Day 1 of
             the study.

          -  Patients must have had an inadequate response to previous anti-TNF⍺ (anti-tumor
             necrosis factor alpha) biological agent(s) for the treatment of RA and meet the
             washout period prior to Day 1 of the study.

        Exclusion Criteria:

          -  Patients receiving oral agents, except for medications listed in inclusion criteria
             for the treatment of RA.

          -  Patients who have previously received any other or biological agent for the treatment
             of RA, other than anti-TNF⍺ inhibitor(s).

          -  Patients who have a current or past history of hepatitis B virus (HBV) infection;
             positive test for hepatitis C virus (HCV) antibody; positive test for human
             immunodeficiency virus (HIV); history of or concurrent interstitial pneumonia; acute
             infection requiring oral antibiotics within 2 weeks, or parenteral injection of
             antibiotics within 4 weeks prior to first administration of the study drug; other
             serious infection within 6 months prior to first administration of study drug;
             recurrent herpes zoster or other chronic or recurrent infection within 6 weeks prior
             to first administration of the study drug; past or current granulomatous infections or
             other severe or chronic infection; positive test for tuberculosis (TB) or other
             evidence of TB.

          -  Patients with uncontrolled diabetes mellitus, or uncontrolled hypertension (systolic
             blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg).

          -  Patients with any other inflammatory or rheumatic diseases that could impact the
             evaluation of the effect of the study drug.

          -  Patients with a history of malignancy within 5 years prior to first administration of
             the study drug, except completely excised and cured squamous cell carcinoma, carcinoma
             of the cervix in situ, cutaneous basal cell carcinoma, or cutaneous squamous cell
             carcinoma.

          -  New York Heart Association (NYHA) class III or IV heart failure, severe uncontrolled
             cardiac disease or heart attack within 6 months prior to first administration of the
             study drug.

          -  Female patients who are currently pregnant, breastfeeding or planning to become
             pregnant or breastfeed within 6 months of the last dose of the study drug.

        Other protocol-defined inclusion/exclusion criteria could apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information</last_name>
    <phone>please email:</phone>
    <email>OscotecOSCO-P2201.SM@ppdi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3110)</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Site 3110 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3105)</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 3105 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational (Site 3104)</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 3104 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3112)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Site 3112 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3108)</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 3108 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3102)</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 3102 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3107)</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Site 3107 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (3106)</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 3106 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3111)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Site 3111 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3109)</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 3109 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3103)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Site 3103 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3101)</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 3101 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2101)</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Site 2101 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2102)</name>
      <address>
        <city>Zlín</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 2102 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2208)</name>
      <address>
        <city>Wrocław</city>
        <state>Dolnoslaskie</state>
        <zip>53-224</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 2208 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2204)</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 2204 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2207)</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-582</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Site 2207 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2202)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-518</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 2202 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2201)</name>
      <address>
        <city>Białystok</city>
        <state>Podlaskie</state>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Site 2201 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2209)</name>
      <address>
        <city>Ostrowiec Świętokrzyski</city>
        <state>Swietokrzyskie</state>
        <zip>27-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 2209 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2203)</name>
      <address>
        <city>Poznań</city>
        <state>Wielkopolskie</state>
        <zip>61-397</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Site 2203 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2206)</name>
      <address>
        <city>Nadarzyn</city>
        <zip>05-830</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Site 2206 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2307)</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 2307 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2304)</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 2304 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2305)</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Site 2305 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2308)</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 2308 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2306)</name>
      <address>
        <city>Ryazan'</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 2306 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2302)</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 2302 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2303)</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 2303 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2303)</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 2303 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2301)</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Site 2301 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2510)</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <state>Ivano-Frankivs'ka Oblast</state>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Site 2510 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2505)</name>
      <address>
        <city>Ternopil'</city>
        <state>Ternopil's'ka Oblast'</state>
        <zip>46002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 2505 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2506)</name>
      <address>
        <city>Vinnytsia</city>
        <state>Vinnyts'ka Oblast'</state>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 2506 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2504)</name>
      <address>
        <city>Vinnytsia</city>
        <state>Vinnyts'ka Oblast'</state>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Site 2504 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2508)</name>
      <address>
        <city>Kharkiv</city>
        <zip>61058</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 2508 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2501)</name>
      <address>
        <city>Kyiv</city>
        <zip>01023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 2501 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2503)</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 2503 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2502)</name>
      <address>
        <city>Kyiv</city>
        <zip>4107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Contact Site 2502 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2507)</name>
      <address>
        <city>Poltava</city>
        <zip>36024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 2507 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2509)</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Site 2509 (NCT 04057118)</last_name>
      <email>OscotecOSCO-P2201.SM@ppdi.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 13, 2019</study_first_submitted>
  <study_first_submitted_qc>August 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>October 24, 2019</last_update_submitted>
  <last_update_submitted_qc>October 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

